Total Funding
51
43
Total FundingGrant raised
Growth Score
-3 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
194339
Development of 1st-in-class personalized organometallic with a unique & innovative mode of action coupled with nanoparticle
Franck Pradier: CEOPast Role: Inakys, Managing Partner
About the Company
Feroscan was set up in 2014 at the initiative of its four founders bringing together scientific and business skills. Feroscan specializes in the development of first-in-class personalized cytotoxics with a unique and innovative mode of action. The pipeline of the company focuses on intractable cancers; such as ovarian, triple negative breast and
NSCL cancers. Feroscan’s business strategy is to test in parallel several preclinical programs on several orphan applications up to proof of concept, IND and early clinical stages. Feroscan is based on a strong IP strategy, cutting edge science and relies on a strong academic and industrial network worldwide to develop clinical applications of its research programs.
